Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus: an Open-Label, Single-Arm, Exploratory Study
Sponsor: Mayo Clinic
Listed as NCT04256759, this PHASE2 trial focuses on Pruritus and remains completed. Sponsored by Mayo Clinic, it has been updated 13 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 8 earlier versions
-
Nov 2023 — Jun 2024 [monthly]
Recruiting PHASE2
-
Jan 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
Dec 2021 — Jan 2023 [monthly]
Recruiting PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Aug 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2020 — Apr 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Mayo Clinic
- Regeneron Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .